You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydromorphone
Accession NumberDB00327  (APRD01021)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionAn opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]
Structure
Thumb
Synonyms
(-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
6-Deoxy-7,8-dihydro-6-oxomorphine
7,8-Dihydromorphinone
Dihydromorfinon
Dihydromorphinone
Dimorphone
Hidromorfona
Hydromorfona
Hydromorphone
Hydromorphonum
Idromorfone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DilaudidSuppository3 mgRectalPurdue Pharma1984-12-312010-08-05Canada
DilaudidInjection, solution4 mg/mLIntramuscular; Intravenous; SubcutaneousPurdue Pharma LP1926-01-01Not applicableUs
DilaudidLiquid2 mgIntramuscular; Intravenous; SubcutaneousPurdue Pharma1984-12-31Not applicableCanada
DilaudidTablet2 mg/1OralPurdue Pharma LP1956-01-01Not applicableUs
DilaudidTablet4 mg/1OralCardinal Health1926-01-01Not applicableUs
DilaudidTablet1 mgOralPurdue Pharma1986-12-31Not applicableCanada
DilaudidTablet2 mgOralPurdue Pharma1984-12-31Not applicableCanada
DilaudidTablet4 mg/1OralPurdue Pharma LP1956-01-01Not applicableUs
DilaudidLiquid1 mgOralPurdue Pharma1989-12-31Not applicableCanada
DilaudidTablet4 mg/1OralLake Erie Medical DBA Quality Care Products LLC1956-01-01Not applicableUs
DilaudidPowder, for solution250 mgIntramuscular; Intravenous; SubcutaneousPurdue Pharma1994-12-312013-06-07Canada
DilaudidInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousPurdue Pharma LP1926-01-01Not applicableUs
DilaudidTablet4 mgOralPurdue Pharma1984-12-31Not applicableCanada
DilaudidTablet8 mgOralPurdue Pharma1989-12-31Not applicableCanada
DilaudidTablet8 mg/1OralPurdue Pharma LP1956-01-01Not applicableUs
DilaudidLiquid5 mg/5mLOralPurdue Pharma LP1956-01-01Not applicableUs
DilaudidTablet2 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-01Not applicableUs
DilaudidInjection, solution2 mg/mLIntramuscular; Intravenous; SubcutaneousPurdue Pharma LP1926-01-01Not applicableUs
Dilaudid HpInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousPurdue Pharma LP1984-01-112016-05-01Us
Dilaudid HpInjection, powder, lyophilized, for solution10 mg/mLIntramuscular; Intravenous; SubcutaneousPurdue Pharma LP1984-01-112016-07-01Us
Dilaudid HpLiquid10 mgIntramuscular; Intravenous; SubcutaneousPurdue Pharma1984-12-31Not applicableCanada
Dilaudid-HP-plusSolution20 mgIntramuscular; Intravenous; SubcutaneousPurdue Pharma1995-12-312012-08-02Canada
Dilaudid-XPLiquid50 mgIntramuscular; Intravenous; SubcutaneousPurdue Pharma1995-12-312012-08-02Canada
ExalgoTablet, extended release16 mg/1OralMallinckrodt, Inc2011-03-14Not applicableUs
ExalgoTablet, extended release8 mg/1OralPhysicians Total Care, Inc.2012-12-31Not applicableUs
ExalgoTablet, extended release12 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
ExalgoTablet, extended release32 mg/1OralMallinckrodt, Inc2012-08-24Not applicableUs
ExalgoTablet, extended release8 mg/1OralSTAT Rx USA LLC2011-03-14Not applicableUs
ExalgoTablet, extended release16 mg/1OralPhysicians Total Care, Inc.2012-12-31Not applicableUs
ExalgoTablet, extended release16 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
ExalgoTablet, extended release8 mg/1OralMallinckrodt, Inc2011-03-14Not applicableUs
ExalgoTablet, extended release8 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
ExalgoTablet, extended release12 mg/1OralMallinckrodt, Inc2011-03-14Not applicableUs
Hydromorph ContinCapsule, extended release9.0 mgOralPurdue Pharma2011-04-14Not applicableCanada
Hydromorph ContinCapsule, extended release4.5 mgOralPurdue Pharma2011-04-14Not applicableCanada
Hydromorph Contin-controlled Release Cap - 12mgCapsule, extended release12 mgOralPurdue Pharma1996-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 18mgCapsule, extended release18 mgOralPurdue Pharma2001-07-03Not applicableCanada
Hydromorph Contin-controlled Release Cap - 24mgCapsule, extended release24 mgOralPurdue Pharma1996-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 30mgCapsule, extended release30 mgOralPurdue Pharma1998-02-16Not applicableCanada
Hydromorph Contin-controlled Release Cap - 3mgCapsule, extended release3 mgOralPurdue Pharma1995-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 6mgCapsule, extended release6 mgOralPurdue Pharma1995-12-31Not applicableCanada
Hydromorph.ir - 2mgTablet2 mgOralPurdue Pharma2002-12-192012-08-02Canada
Hydromorph.ir - 4mgTablet4 mgOralPurdue Pharma2002-12-192012-08-02Canada
Hydromorph.ir - 8mgTablet8 mgOralPurdue Pharma2002-12-192012-08-02Canada
HydromorphoneTablet4 mgOralSorres Pharma Inc2004-04-062014-06-20Canada
HydromorphoneTablet1 mgOralSorres Pharma Inc2004-04-062014-06-20Canada
HydromorphoneTablet8 mgOralSorres Pharma Inc2004-04-062014-06-20Canada
HydromorphoneTablet2 mgOralSorres Pharma Inc2004-04-062014-06-20Canada
Hydromorphone HCl Tab 2mg USPTablet2 mgOralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Hydromorphone HCl Tab 4mg USPTablet4 mgOralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Hydromorphone Hp 10Solution10 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp 20Solution20 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp 50Solution50 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp Forte InjectionSolution100 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated2001-12-10Not applicableCanada
Hydromorphone HydrochlorideInjection, solution4 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1Oralbryant ranch prepack2009-11-23Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralSTAT Rx USA LLC2009-11-23Not applicableUs
Hydromorphone HydrochlorideInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1Oralbryant ranch prepack2009-11-23Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone HydrochlorideInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideInjection, solution4 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone HydrochlorideInjection, solution2 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideInjection, solution2 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideSolution5 mg/5mLOralRhodes Pharmaceuticals L.P.2012-07-20Not applicableUs
Hydromorphone HydrochlorideInjection, solution2 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralAvera Mc Kennan Hospital2015-05-28Not applicableUs
Hydromorphone Hydrochloride Extended-releaseTablet, extended release8 mg/1OralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releaseTablet, extended release12 mg/1OralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releaseTablet, extended release16 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releaseTablet, extended release16 mg/1OralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releaseTablet, extended release32 mg/1OralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Injection USPSolution2 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hydrochloride Injection USP Hp 10Solution10 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation2014-06-11Not applicableCanada
Hydromorphone Hydrochloride Sup 3mgSuppository3 mgRectalSandoz Canada Incorporated1992-12-312012-01-23Canada
JurnistaTablet, extended release8 mgOralJanssen Inc2010-03-04Not applicableCanada
JurnistaTablet, extended release16 mgOralJanssen Inc2010-03-04Not applicableCanada
JurnistaTablet, extended release32 mgOralJanssen Inc2010-03-04Not applicableCanada
JurnistaTablet, extended release4 mgOralJanssen Inc2010-03-04Not applicableCanada
Palladone XL - 12mgCapsule, extended release12 mgOralPurdue Pharma2002-12-192005-08-05Canada
Palladone XL - 16mgCapsule, extended release16 mgOralPurdue Pharma2002-12-192005-08-05Canada
Palladone XL - 24mgCapsule, extended release24 mgOralPurdue Pharma2002-12-192005-08-05Canada
PHL-hydromorphoneSuppository3 mgRectalPharmel IncNot applicableNot applicableCanada
PHL-hydromorphone -syr 1mg/mlSyrup1 mgOralPharmel IncNot applicableNot applicableCanada
PMS Hydromorphone Sirop 1mg/mlSyrup1 mgOralPharmascience Inc1991-12-31Not applicableCanada
PMS Hydromorphone Suppositoire 3mgSuppository3 mgRectalPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 1mgTablet1 mgOralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 2mgTablet2 mgOralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 4mgTablet4 mgOralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 8mgTablet8 mgOralPharmascience Inc1991-12-31Not applicableCanada
Teva-hydromorphoneTablet4 mgOralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphoneTablet8 mgOralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphoneTablet1 mgOralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphoneTablet2 mgOralTeva Canada Limited2011-11-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydromorphoneTablet2 mgOralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphoneTablet4 mgOralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphoneTablet8 mgOralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphoneTablet1 mgOralApotex Inc2012-12-18Not applicableCanada
Hydromorphone HydrochlorideTablet, extended release8 mg/1OralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralAurolife Pharma, LLC2016-05-17Not applicableUs
Hydromorphone HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2008-06-17Not applicableUs
Hydromorphone HydrochlorideTablet, film coated4 mg/1OralPhysicians Total Care, Inc.2004-01-07Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-05-14Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralWest Ward Pharmaceuticals Corp.2009-07-29Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralAmerican Health Packaging2014-08-14Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralSTAT Rx USA LLC2007-09-19Not applicableUs
Hydromorphone HydrochlorideTablet, extended release16 mg/1OralTrigen Laboratories, LLC2016-09-15Not applicableUs
Hydromorphone HydrochlorideTablet, extended release8 mg/1OralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-26Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone HydrochlorideTablet, extended release16 mg/1OralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1Oralbryant ranch prepack2009-07-29Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralAurolife Pharma, LLC2016-05-17Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralLannett Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone HydrochlorideSolution1 mg/mLOralWest Ward Pharmaceuticals Corp.2012-03-01Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet, extended release12 mg/1OralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralSTAT Rx USA LLC2007-09-19Not applicableUs
Hydromorphone HydrochlorideTablet, extended release32 mg/1OralTrigen Laboratories, LLC2016-09-15Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralTAGI Pharma, Inc.2012-03-09Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone HydrochlorideTablet, extended release12 mg/1OralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralAmerican Health Packaging2013-07-17Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet, extended release8 mg/1OralTrigen Laboratories, LLC2016-09-15Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralLannett Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralSTAT Rx USA LLC2009-05-14Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone HydrochlorideTablet, film coated2 mg/1OralPhysicians Total Care, Inc.2004-09-20Not applicableUs
Hydromorphone HydrochlorideTablet, extended release16 mg/1OralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralWest Ward Pharmaceuticals Corp.2009-07-29Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet, extended release32 mg/1OralActavis Pharma, Inc.2016-10-10Not applicableUs
Hydromorphone HydrochlorideInjection, solution10 mg/mLIntramuscular; Intravenous; SubcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone HydrochlorideTablet4 mg/1OralAmerican Health Packaging2013-07-17Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone HydrochlorideTablet, extended release12 mg/1OralTrigen Laboratories, LLC2016-09-15Not applicableUs
Hydromorphone HydrochlorideTablet8 mg/1OralLannett Company, Inc.2009-12-09Not applicableUs
Hydromorphone HydrochlorideInjection10 mg/mLParenteralAkorn, Inc.2010-05-15Not applicableUs
Hydromorphone HydrochlorideTablet2 mg/1OralAurolife Pharma, LLC2016-05-17Not applicableUs
Hydromorphone HydrochlorideTablet, film coated8 mg/1OralPhysicians Total Care, Inc.2002-02-06Not applicableUs
Hyrdomorphone HydrochlorideTablet8 mg/1OralPrecision Dose Inc.2014-02-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydromorphone HClInjection, solution10 mg/mLIntravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone HClInjection, solution.1 mg/mLIntravenousCantrell Drug Company2014-08-21Not applicableUs
Hydromorphone HClInjection, solution.4 mg/mLIntravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone HClInjection, solution.5 mg/mLIntramuscular; Intravenous; SubcutaneousCantrell Drug Company2012-01-18Not applicableUs
Hydromorphone HClInjection, solution2 mg/mLIntravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone HClInjection, solution1 mg/mLIntravenousCantrell Drug Company2011-06-30Not applicableUs
Hydromorphone HClInjection, solution.2 mg/mLIntravenousCantrell Drug Company2010-08-23Not applicableUs
Hydromorphone HydrochlorideSuppository3 mg/1RectalPaddock Laboratories, LLC1996-01-31Not applicableUs
Hydromorphone HydrochlorideInjection2 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1972-01-01Not applicableUs
Hydromorphone HydrochlorideInjection2 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1972-01-01Not applicableUs
International Brands
NameCompany
PalladoneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Hydromorphone Hydrochloride
71-68-1
Thumb
  • InChI Key: XHILEZUETWRSHC-NRGUFEMZSA-N
  • Monoisotopic Mass: 321.113171218
  • Average Mass: 321.799
DBSALT000444
Categories
UNIIQ812464R06
CAS number466-99-9
WeightAverage: 285.3377
Monoisotopic: 285.136493479
Chemical FormulaC17H19NO3
InChI KeyWVLOADHCBXTIJK-YNHQPCIGSA-N
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Pharmacology
IndicationFor the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.
Structured Indications
PharmacodynamicsHydromorphone is a hydrogenated ketone derivative of morphine that acts as a narcotic analgesic. It has a shorter duration of action than morphine. Hydromorphone is approximately 8 times more potent on a milligram basis than morphine. In addition, hydromorphone is better absorbed orally than is morphine. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Hydromorphone appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionHydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinyes
partial agonist
HumanP41143 details
Kappa-type opioid receptorProteinyes
agonist
HumanP41145 details
Related Articles
AbsorptionBetter absorbed orally than morphine
Volume of distributionNot Available
Protein binding20%
Metabolism

Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.

SubstrateEnzymesProduct
Hydromorphone
DihydromorphineDetails
Hydromorphone
DihydroisomorphineDetails
Hydromorphone
NorhydromorphoneDetails
Hydromorphone
Hydromorphone 3-beta-O-glucuronideDetails
Hydromorphone
Not Available
Dihydroisomorphine-6-glucuronideDetails
Hydromorphone
Not Available
Hydromorphone-3-glucosideDetails
Hydromorphone
Not Available
Hydromorphone-3-glucuronideDetails
Hydromorphone
Not Available
Hydromorphone-3-sulphateDetails
Dihydromorphine
Dihydromorphine-3-glucuronideDetails
Route of eliminationOnly a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.
Half life2.6 hours (oral); 18.6 hours for sustained release Palladone
Clearance
  • 1.96 L/min
ToxicityHydromorphone is a schedule II narcotic which can lead to physical dependence or addiction. High doses lead to respiratory depression, nausea, and vomiting. Overdoses lead to extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydromorphone Action PathwayDrug actionSMP00410
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydromorphone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Hydromorphone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydromorphone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Hydromorphone.Experimental
AbirateroneThe serum concentration of Hydromorphone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.Approved
adipiplonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Hydromorphone.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amiloride.Approved
AmiodaroneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydromorphone.Approved
AprepitantThe serum concentration of Hydromorphone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Hydromorphone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine.Approved
AtazanavirThe metabolism of Hydromorphone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Hydromorphone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azaperone.Vet Approved
AzelastineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydromorphone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydromorphone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Hydromorphone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Hydromorphone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Hydromorphone.Investigational
BoceprevirThe metabolism of Hydromorphone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Hydromorphone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydromorphone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.Approved, Investigational
BuprenorphineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Hydromorphone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Hydromorphone.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenone.Investigational
CapecitabineThe metabolism of Hydromorphone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Hydromorphone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Hydromorphone.Withdrawn
CelecoxibThe metabolism of Hydromorphone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Hydromorphone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Hydromorphone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Hydromorphone.Illicit, Withdrawn
ChlorpromazineThe metabolism of Hydromorphone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Hydromorphone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Hydromorphone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Hydromorphone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Hydromorphone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Hydromorphone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Hydromorphone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium.Approved
ClobazamThe metabolism of Hydromorphone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Hydromorphone can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Hydromorphone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Hydromorphone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Hydromorphone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Hydromorphone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone.Approved, Illicit
ConivaptanThe serum concentration of Hydromorphone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Hydromorphone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydromorphone.Approved
CyclosporineThe metabolism of Hydromorphone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydromorphone.Approved
DapoxetineHydromorphone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Hydromorphone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Hydromorphone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Hydromorphone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.Approved
DesipramineThe metabolism of Hydromorphone can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.Approved
DesvenlafaxineHydromorphone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Hydromorphone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Hydromorphone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Hydromorphone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.Approved
DoxycyclineThe metabolism of Hydromorphone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
DronedaroneThe metabolism of Hydromorphone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Hydromorphone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Hydromorphone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Hydromorphone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine.Approved
EliglustatThe metabolism of Hydromorphone can be decreased when combined with Eliglustat.Approved
EluxadolineHydromorphone may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Hydromorphone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone.Approved
ErythromycinThe metabolism of Hydromorphone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramHydromorphone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Hydromorphone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.Approved
EthanolHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydromorphone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydromorphone.Approved
EtoperidoneHydromorphone may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Hydromorphone can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.Approved
FloxuridineThe metabolism of Hydromorphone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Hydromorphone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Hydromorphone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Hydromorphone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Hydromorphone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Hydromorphone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Hydromorphone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hydromorphone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Hydromorphone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydromorphone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydromorphone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Hydromorphone can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Hydromorphone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydromorphone.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hydromorphone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Hydromorphone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone.Approved
IdelalisibThe serum concentration of Hydromorphone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.Approved
ImatinibThe metabolism of Hydromorphone can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Hydromorphone can be decreased when combined with Imipramine.Approved
IndalpineHydromorphone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.Approved
IndinavirThe metabolism of Hydromorphone can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hydromorphone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydromorphone.Withdrawn
IrbesartanThe metabolism of Hydromorphone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Hydromorphone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydromorphone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Hydromorphone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Isosorbide.Approved
IsradipineThe metabolism of Hydromorphone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Hydromorphone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Hydromorphone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Hydromorphone can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Hydromorphone is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Hydromorphone can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate.Approved
LevomilnacipranHydromorphone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Hydromorphone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Hydromorphone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Hydromorphone can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hydromorphone.Approved
LorcaserinThe metabolism of Hydromorphone can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Hydromorphone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Hydromorphone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Hydromorphone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydromorphone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Hydromorphone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hydromorphone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Hydromorphone.Investigational
MephentermineMephentermine may increase the analgesic activities of Hydromorphone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.Approved
MethadoneThe metabolism of Hydromorphone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.Approved
MethotrimeprazineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hydromorphone.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.Approved
MetoprololThe metabolism of Hydromorphone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineHydromorphone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Hydromorphone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranHydromorphone may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydromorphone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Investigational
MirabegronThe metabolism of Hydromorphone can be decreased when combined with Mirabegron.Approved
MirtazapineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Hydromorphone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Hydromorphone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydromorphone.Approved
ModafinilThe serum concentration of Hydromorphone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Hydromorphone.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Hydromorphone.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Investigational
NafcillinThe serum concentration of Hydromorphone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Hydromorphone.Approved
NaltrexoneThe therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Hydromorphone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Hydromorphone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Hydromorphone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Hydromorphone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydromorphone.Withdrawn
NicardipineThe metabolism of Hydromorphone can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Hydromorphone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Hydromorphone.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydromorphone.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Hydromorphone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Hydromorphone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Opium.Approved, Illicit
OrphenadrineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Hydromorphone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydromorphone.Approved
PalbociclibThe serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.Approved
PanobinostatThe serum concentration of Hydromorphone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydromorphone.Approved
ParoxetineThe metabolism of Hydromorphone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.Approved
PentazocinePentazocine may decrease the analgesic activities of Hydromorphone.Approved, Vet Approved
PentobarbitalThe metabolism of Hydromorphone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydromorphone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved
PerazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydromorphone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Hydromorphone.Withdrawn
PhenobarbitalThe metabolism of Hydromorphone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Hydromorphone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
PhenytoinThe metabolism of Hydromorphone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydromorphone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Hydromorphone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Hydromorphone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleHydromorphone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hydromorphone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Hydromorphone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.Approved
PromazineThe metabolism of Hydromorphone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Hydromorphone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydromorphone.Investigational
PropofolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Hydromorphone is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Hydromorphone.Approved
PyrimethamineThe metabolism of Hydromorphone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone.Approved
QuinidineThe metabolism of Hydromorphone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Hydromorphone can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.Approved, Investigational
RamosetronHydromorphone may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Hydromorphone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydromorphone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.Approved
RifabutinThe metabolism of Hydromorphone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Hydromorphone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Hydromorphone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Hydromorphone.Investigational
RitonavirThe metabolism of Hydromorphone can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Hydromorphone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Romifidine.Vet Approved
RopiniroleHydromorphone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone.Approved
RotigotineHydromorphone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydromorphone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Hydromorphone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydromorphone.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sage 547.Investigational
SaquinavirThe metabolism of Hydromorphone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydromorphone.Approved
SecobarbitalThe metabolism of Hydromorphone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydromorphone.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Hydromorphone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Hydromorphone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Hydromorphone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Hydromorphone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone.Approved
SorafenibThe metabolism of Hydromorphone can be decreased when combined with Sorafenib.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Hydromorphone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Hydromorphone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydromorphone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Hydromorphone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.Approved
SuvorexantHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Hydromorphone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Hydromorphone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone.Approved
TerbinafineThe metabolism of Hydromorphone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrodotoxin.Investigational
ThalidomideHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Hydromorphone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Hydromorphone can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride.Investigational
TicagrelorThe metabolism of Hydromorphone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Hydromorphone can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydromorphone.Approved
TipranavirThe metabolism of Hydromorphone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Hydromorphone can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hydromorphone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydromorphone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone.Approved
TrimethoprimThe metabolism of Hydromorphone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydromorphone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.Approved
Uc1010The risk or severity of adverse effects can be increased when Hydromorphone is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydromorphone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Hydromorphone.Approved, Investigational
ValsartanThe metabolism of Hydromorphone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.Approved
VenlafaxineThe metabolism of Hydromorphone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Hydromorphone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Hydromorphone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Hydromorphone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.Approved
ZimelidineHydromorphone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Hydromorphone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolazepam.Vet Approved
ZolpidemHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, “Morphinone reductase for the preparation of hydromorphone and hydrocodone.” U.S. Patent US5571685, issued November, 1990.

US5571685
General References
  1. Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953 ]
  2. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981 Apr;21(4):152-6. [PubMed:6165742 ]
External Links
ATC CodesN02AG04N02AA03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (78.9 KB)
MSDSDownload (48.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9931
Caco-2 permeable+0.8647
P-glycoprotein substrateSubstrate0.8174
P-glycoprotein inhibitor INon-inhibitor0.8497
P-glycoprotein inhibitor IINon-inhibitor0.9641
Renal organic cation transporterInhibitor0.6374
CYP450 2C9 substrateNon-substrate0.7925
CYP450 2D6 substrateSubstrate0.8618
CYP450 3A4 substrateSubstrate0.7571
CYP450 1A2 substrateNon-inhibitor0.6918
CYP450 2C9 inhibitorNon-inhibitor0.9539
CYP450 2D6 inhibitorNon-inhibitor0.5197
CYP450 2C19 inhibitorNon-inhibitor0.8088
CYP450 3A4 inhibitorNon-inhibitor0.8177
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9413
Ames testNon AMES toxic0.7214
CarcinogenicityNon-carcinogens0.9554
BiodegradationNot ready biodegradable0.9815
Rat acute toxicity2.9191 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8906
hERG inhibition (predictor II)Non-inhibitor0.8992
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purdue pharma lp
  • Purdue pharmaceutical products lp
  • Akorn inc
  • Barr laboratories inc
  • Hospira inc
  • Watson laboratories inc
  • Roxane laboratories inc
  • Mallinckrodt inc
  • Actavis totowa llc
  • Kv pharmaceutical co
  • Lannett holdings inc
  • Tyco healthcare mallinckrodt
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous; Subcutaneous2 mg
LiquidOral1 mg
LiquidOral5 mg/5mL
Powder, for solutionIntramuscular; Intravenous; Subcutaneous250 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous; Subcutaneous10 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
LiquidIntramuscular; Intravenous; Subcutaneous50 mg
Capsule, extended releaseOral4.5 mg
Capsule, extended releaseOral9.0 mg
Capsule, extended releaseOral12 mg
Capsule, extended releaseOral18 mg
Capsule, extended releaseOral24 mg
Capsule, extended releaseOral30 mg
Capsule, extended releaseOral3 mg
Capsule, extended releaseOral6 mg
Injection, solutionIntramuscular; Intravenous; Subcutaneous.5 mg/mL
Injection, solutionIntravenous.1 mg/mL
Injection, solutionIntravenous.2 mg/mL
Injection, solutionIntravenous.4 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous2 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous20 mg
SolutionIntramuscular; Intravenous; Subcutaneous50 mg
SolutionIntramuscular; Intravenous; Subcutaneous100 mg
InjectionIntramuscular; Intravenous; Subcutaneous2 mg/mL
InjectionParenteral10 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous1 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous10 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous2 mg/mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous4 mg/mL
SolutionOral1 mg/mL
SolutionOral5 mg/5mL
SuppositoryRectal3 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral8 mg/1
Tablet, extended releaseOral12 mg/1
Tablet, extended releaseOral16 mg/1
Tablet, extended releaseOral32 mg/1
Tablet, extended releaseOral8 mg/1
SolutionIntramuscular; Intravenous; Subcutaneous2 mg
Tablet, extended releaseOral16 mg
Tablet, extended releaseOral32 mg
Tablet, extended releaseOral4 mg
Tablet, extended releaseOral8 mg
Capsule, extended releaseOral16 mg
SyrupOral1 mg
SuppositoryRectal3 mg
TabletOral1 mg
TabletOral2 mg
TabletOral4 mg
TabletOral8 mg
Prices
Unit descriptionCostUnit
Hydromorphone hcl powder166.25USD g
Dilaudid-hp 250 mg vial114.8USD vial
Dilaudid Sterile Powder 250 mg/vial78.99USD vial
HYDROmorphone HCl 6 3 mg Suppository Box54.92USD box
Hydromorphone Hp 50 50 mg/ml13.78USD ml
Dilaudid-Xp 50 mg/ml11.82USD ml
Hydromorphone 3 mg suppository11.11USD suppository
Dilaudid-Hp-Plus 20 mg/ml5.08USD ml
Hydromorphone Hp 20 20 mg/ml4.72USD ml
Hydromorph Contin 30 mg Controlled-Release Capsule4.21USD capsule
Hydromorph Contin 24 mg Controlled-Release Capsule3.52USD capsule
Dilaudid-Hp 10 mg/ml3.14USD ml
Hydromorphone Hp 10 mg/ml2.92USD ml
Hydromorph Contin 18 mg Controlled-Release Capsule2.75USD capsule
Hydromorphone 10 mg/ml ampul2.58USD ml
Pms-Hydromorphone 3 mg Suppository2.42USD suppository
Dilaudid 4 mg/ml ampul2.2USD ml
Dilaudid 8 mg tablet2.19USD tablet
HYDROmorphone HCl 4 mg/ml Solution 1ml Cartridge2.07USD cartridge
Hydromorph Contin 12 mg Controlled-Release Capsule1.91USD capsule
Dilaudid 2 mg/ml ampul1.81USD ml
Dilaudid 1 mg/ml ampul1.64USD ml
Hydromorphone hcl 8 mg tablet1.4USD tablet
Dilaudid 4 mg tablet1.36USD tablet
Hydromorphone 8 mg tablet1.32USD tablet
Dilaudid 2 mg/ml1.28USD ml
Hydromorphone 2 mg/ml1.19USD ml
Hydromorph Contin 6 mg Controlled-Release Capsule1.1USD capsule
Hydromorphone-ns 0.4 mg/ml1.08USD ml
Hydromorphone-ns 0.3 mg/ ml1.05USD ml
Hydromorphone 2 mg/ml vial1.02USD ml
Hydromorphone-ns 25 mg/25 ml1.01USD ml
Dilaudid 2 mg tablet1.0USD tablet
Hydromorphone-ns 2.5 mg/25 ml0.96USD ml
HYDROmorphone HCl 4 mg tablet0.8USD tablet
HYDROmorphone HCl 2 mg tablet0.77USD tablet
Hydromorph Contin 3 mg Controlled-Release Capsule0.73USD capsule
Hydromorphone 4 mg tablet0.72USD tablet
Dilaudid 8 mg Tablet0.55USD tablet
Hydromorphone-ns 0.2 mg/ml0.49USD ml
Hydromorphone 2 mg tablet0.37USD tablet
Pms-Hydromorphone 8 mg Tablet0.37USD tablet
Dilaudid 4 mg Tablet0.35USD tablet
Dilaudid-5 1 mg/ml liquid0.33USD ml
Hydromorphone-ns 5.5 mg/55 ml0.33USD ml
Dilaudid 2 mg Tablet0.23USD tablet
Pms-Hydromorphone 4 mg Tablet0.23USD tablet
Dilaudid 1 mg Tablet0.16USD tablet
Pms-Hydromorphone 2 mg Tablet0.15USD tablet
Pms-Hydromorphone 1 mg Tablet0.1USD tablet
Dilaudid 1 mg/ml Liquid0.09USD ml
Pms-Hydromorphone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5968551 No1994-12-242011-12-24Us
US6589960 No2000-11-092020-11-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point266.5 °CPhysProp
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.39 mg/mLALOGPS
logP1.69ALOGPS
logP1.62ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.26 m3·mol-1ChemAxon
Polarizability30.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-002r-6960000000-9f3d9b17d56e032d76c5View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447. [PubMed:11869661 ]
  2. Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13. [PubMed:12479250 ]
  3. Sarhill N, Walsh D, Nelson KA: Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96. [PubMed:11305075 ]
  4. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC: Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30. [PubMed:18789923 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Fang X, Larson DL, Portoghese PS: 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. J Med Chem. 1997 Sep 12;40(19):3064-70. [PubMed:9301669 ]
  2. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950 ]
  3. Jiang Q, Sebastian A, Archer S, Bidlack JM: 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther. 1994 Mar;268(3):1107-13. [PubMed:7511163 ]
  4. Guay DR: Use of oral oxymorphone in the elderly. Consult Pharm. 2007 May;22(5):417-30. [PubMed:17658959 ]
  5. Hartvig P, Neil A, Terenius L, Antoni G, Rimland A, Ulin J, Langstrom B: Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species. Pharmacol Toxicol. 1989 Sep;65(3):214-6. [PubMed:2478994 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J: Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. [PubMed:16433932 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:41